In re: MDL 2700 Genentech, Inc. Herceptin (Traztuzumab) Marketing and Sales Litigation

U.S. Court of Appeals for the Tenth Circuit

Tab Group

Merits Stage

U.S. Chamber urges Tenth Circuit to hold that federal law preempts state-law claims challenging statements on a prescription drug’s label concerning the amount of the drug included in a vial

October 11, 2019

Click here to view the Chamber’s amicus brief.

Jeremy M. Bylund, Jeffrey S. Bucholtz, Marisa C. Maleck, and Gabriel Krim of King & Spalding LLP served as co-counsel for the U.S. Chamber of Commerce on behalf of the U.S. Chamber Litigation Center.

Case Documents

Appellants' Opening Brief (Redacted) -- In re MDL 2700 Genentech, Inc. Herceptin (Traztuzumab) Marketing and Sales Litigation (Tenth Circuit).pdf

U.S. Chamber Amicus Brief -- In re MDL 2700 Genentech, Inc. Herceptin (Traztuzumab) Marketing and Sales Litigation (Tenth Circuit).pdf